Metastatic prostate cancer with a normal prostate-specific antigen level.
Prostate-specific antigen (PSA) is the most commonly used tumour marker for prostate cancer, both in screening and in follow-up. However, there are many false positive increases in the presence of other prostate diseases and, currently, there is no consensus regarding sensitivity and specificity of the PSA test, nor what constitutes the upper limit of normality. We report a case of a 67-year-old patient with metastatic prostate cancer who, with increased level of alkaline phosphatase and normal PSA, showed clinical and radiological evidence of progression of the disease.
Ruiz-Martín
Isabel
I
Servicio de Oncología Médica, Hospital Universitario de Salamanca, Paseo San Vicente 58-182, 37007 Salamanca, Spain. mruizmartin@hotmail.com
Rodríguez-Sánchez
César A
CA
Ocaña-Fernández
Alberto
A
del Valle-Zapico
Javier
J
Soto de Prado-Otero
Diego
D
Cruz-Hernández
Juan J
JJ
D000230:Adenocarcinoma / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary*; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D011877:Radionuclide Imaging; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D017430:Prostate-Specific Antigen